Xiaolan Yong
YOU?
Author Swipe
View article: Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum] Open
[This corrects the article DOI: 10.2147/DDDT.S500384.].
View article: Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study Open
HRS-1780 PK and safety profiles did not differ significantly between healthy and renal impairment subjects. This supports the drug dose regimen for renal impairment patients in clinical practice.
View article: Yogliptin monotherapy in type 2 diabetes: A 12‐week randomized, double‐blind, placebo‐controlled phase <scp>II</scp> study
Yogliptin monotherapy in type 2 diabetes: A 12‐week randomized, double‐blind, placebo‐controlled phase <span>II</span> study Open
Background The new xanthine dipeptidyl peptidase‐4 inhibitor yogliptin has exhibited excellent hypoglycemic activity in experimental disease models. The present work aimed to assess the efficacy of yogliptin as a monotherapy in individuals…
View article: Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China
Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China Open